Leucine-Alanine (L-Leucyl-L-Alanine): A Comprehensive Reference
1. Identity and Chemical Characterization
Chemical Names and Identifiers
L-Leucyl-L-Alanine is a dipeptide composed of L-leucine and L-alanine joined by a peptide linkage. It is most precisely designated by its IUPAC systematic name and is catalogued in the chemical literature under a variety of synonyms: these include Leu-Ala, Leucylalanine, NSC 89180, NSC-89180, H-LEU-ALA-OH, and L-Leucine-L-Alanine, with the CAS Registry Number 7298-84-2 and the molecular formula C₉H₁₈N₂O₃ (exact molecular weight 202.13 Da).
The chemical formula for this dipeptide is C₉H₁₈N₂O₃, and it features an amine group, a carboxylic acid group, and a side chain characteristic of each constituent amino acid. It is characterized by its specific sequence, in which leucine is linked to alanine through a peptide bond — specifically, the alpha-carboxyl group of L-leucine forms a covalent amide bond with the alpha-amino group of L-alanine. The notation "L-Leucyl-L-Alanine" (or H-Leu-Ala-OH in peptide shorthand) specifies that leucine occupies the N-terminal position and alanine occupies the C-terminal position. The reversed sequence — L-alanyl-L-leucine (Ala-Leu) — is a structurally distinct isomer with a different CAS number and should not be conflated with Leu-Ala.
L-Leucyl-L-Alanine exhibits properties common to peptides, such as solubility in water and the ability to form hydrogen bonds, which contribute to its stability and functionality in biological environments. The presence of the hydrophobic leucine side chain can influence its interactions with other molecules, while the smaller, polar alanine residue can facilitate solubility.
Constituent Amino Acids
L-Leucine is an essential branched-chain amino acid (BCAA); it cannot be synthesized by the human body and must be obtained through diet. Leucine is one of the essential branched-chain amino acids and has many roles in protein and energy metabolism. L-Alanine, in contrast, is a non-essential, small aliphatic alpha-amino acid that the body can synthesize endogenously. When muscles degrade amino acids for energy needs, the resulting nitrogen is transaminated to pyruvate to form alanine, performed by the enzyme alanine transaminase (ALT), which converts L-glutamate and pyruvate into alpha-ketoglutarate and L-alanine; the resulting L-alanine is then shuttled to the liver, where the nitrogen enters the urea cycle and the pyruvate is used to make glucose. The juxtaposition of these two amino acids within the same dipeptide makes Leu-Ala a compound that bridges BCAA anabolism with gluconeogenic nitrogen transport.
Common Synonyms
- L-Leucyl-L-Alanine
- H-Leu-Ala-OH
- Leu-Ala
- Leucylalanine
- L-Leucine-L-Alanine
- NSC 89180
2. Natural Sources and Biological Occurrence
Endogenous Occurrence
This compound is typically found in various biological systems and can play a role in protein synthesis and metabolism. L-Leucyl-L-Alanine is classifiable as an endogenous metabolite — a compound that arises naturally within living organisms as a product of protein catabolism and peptide bond hydrolysis. As a metabolite, it is involved in various metabolic pathways and can influence protein synthesis and cellular functions. It appears in human plasma and tissues as a short-lived intermediate whenever leucine-alanine sequences within larger proteins are cleaved by proteolytic enzymes during normal protein turnover. Its transient presence in plasma after dietary protein ingestion reflects the well-established finding that constituent amino acids are absorbed faster when digested as dipeptides versus free amino acids.
Dietary and Food Sources
Leu-Ala is not uniquely abundant in any single food source in quantities that have been characterised by direct measurement in the peer-reviewed literature. However, as a product of proteolysis, it occurs wherever leucine-alanine sequences exist in dietary proteins. Leucine is one of the most prevalent amino acids in animal-source proteins (meat, dairy, eggs), and alanine is ubiquitous across both animal and plant protein matrices. Proteolysis of meat proteins is one of the important processes that occur during the preservation of meat by fermentation; during the fermentation of meat into fermented products such as dry-cured ham and fermented sausages, proteolytic degradation certainly results in the generation of bioactive peptides. The specific dipeptide Leu-Ala may be generated in such matrices, though direct quantitation of Leu-Ala in fermented foods has not been confirmed in the sources available for this review.
In fermented dairy products, extensive proteolysis by lactic acid bacteria generates a broad spectrum of dipeptides. Fermented milk products are rich in dipeptides from leucine and alanine-containing protein sequences, produced by proteolytic starter cultures including Lactobacillus helveticus, L. bulgaricus, and Streptococcus thermophilus. Bioactive peptides (BAPs) consist of 2 to 20 amino acids originating from precursor proteins following an activation process involving multiple reactions such as chemical hydrolysis, enzymatic hydrolysis operated by proteolytic enzymes, or microbial fermentation by proteolytic bacteria.
Fermentation: microbial fermentation processes can yield this dipeptide as part of broader metabolic pathways involving amino acids. Enzymatic hydrolysis of whey, casein, and meat proteins — whether performed during food processing or gastrointestinal digestion — is the primary route by which Leu-Ala becomes transiently available as an intact dipeptide in biological systems.
Common Preparation and Forms
In research and commercial contexts, L-Leucyl-L-Alanine is available as a synthetic compound produced by chemical peptide synthesis (condensation reaction with peptidyl transferase-class catalysis) or enzymatic synthesis. The formation of L-Leucyl-L-Alanine involves a condensation reaction where water is released during the bonding of the two amino acids; this reaction can be catalyzed by enzymes known as peptidyl transferases, which facilitate peptide bond formation during protein synthesis. L-Leucyl-L-Alanine can also undergo hydrolysis, breaking down into its constituent amino acids under acidic or enzymatic conditions. In supplement contexts, it may appear in preparations described as "leucine peptides" or "protein hydrolysates," though it is rarely labelled as a discrete ingredient. It is sometimes included in dietary supplements aimed at enhancing muscle growth and recovery.
3. Traditional and Historical Use
L-Leucyl-L-Alanine as an isolated, characterised compound has no documented history of traditional or pre-modern use. It is not described in any classical herbal pharmacopoeia, traditional Chinese medicine (TCM) materia medica, Ayurvedic formularies, Western folk medicine traditions, or official ethnobotanical records. The compound was first identified and named in the context of twentieth-century biochemistry and peptide chemistry, not in traditional practice.
What does exist is a long, cross-cultural history of consuming foods that, through digestion, yield this dipeptide transiently as part of normal protein metabolism. Fermented foods rich in BCAA-containing proteins — such as aged cheeses, cured meats, fermented fish, miso, tempeh, and yoghurt — have been dietary staples in many cultures for centuries, and their proteolytic products include a spectrum of leucine- and alanine-containing peptides. However, attribution of any specific traditional therapeutic purpose to L-Leucyl-L-Alanine as a discrete entity would not be historically accurate, and no such attribution is made here. The scientific characterization and bioactivity profiling of this specific dipeptide is entirely a product of modern analytical chemistry.
4. Key Constituents and Mechanisms of Action
Structural Basis of Activity
L-Leucyl-L-Alanine exerts its biological effects both through direct action of the intact dipeptide and, upon hydrolysis, through delivery of its constituent amino acids. These two modes of action are biochemically distinct.
4.1 Inhibition of Ubiquitin-Mediated Protein Degradation
The most consistently documented bioactivity of L-Leucyl-L-Alanine as an intact dipeptide in the biochemical literature is its capacity to interfere with protein degradation. L-Leucyl-L-Alanine is a dipeptide found to inhibit ubiquitin-mediated protein degradation. The ubiquitin-proteasome system (UPS) is the principal intracellular pathway for the targeted breakdown of damaged, misfolded, and regulatory proteins. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins; the ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining homeostasis within cells. By inhibiting this pathway, Leu-Ala could, in principle, reduce excessive protein catabolism — which is of potential relevance in muscle-wasting conditions. However, it must be emphasized that evidence for this activity in intact humans is limited to in vitro and early experimental data; no clinical trials specifically examining Leu-Ala's effect on the UPS in humans were identified in the literature reviewed.
L-Leucyl-L-Alanine has been investigated through in vitro experiments to understand its effects on cell cultures, specifically its impact on cell growth and differentiation; although the mechanism of action of L-Leucyl-L-Alanine is not entirely understood, it is hypothesized to function as a substrate for enzymes that play a role in protein synthesis and energy metabolism.
4.2 The PepT1 Dipeptide Transporter and Absorption
A key mechanistic rationale for the potential advantage of leucine-containing dipeptides over free leucine is the intestinal peptide transporter PepT1 (gene: SLC15A1). PepT1 is located in the apical membrane of enterocytes and has a high capacity to absorb peptides, exhibiting a broad substrate-specificity covering more than 400 different dipeptides and more than 8,000 tripeptides. Leu-containing dipeptides are transported into the intestinal endothelium via the PepT1 H⁺/peptide cotransporter, potentially making them more rapidly available to muscle tissue, expediting and amplifying anabolic effects post-ingestion. This transporter operates via a mechanism independent of the amino acid transporters that free leucine must compete through, which may offer a kinetic advantage under conditions of mixed amino acid intake.
There is evidence suggesting the potential of di- and tripeptides to avoid cytosolic hydrolysis, thereby allowing for intact transport across the basolateral membrane. This means that a proportion of an ingested leucine-alanine dipeptide may reach the portal circulation intact, before being hydrolysed in peripheral tissues.
4.3 Leucine-Driven mTORC1 Signalling and Muscle Protein Synthesis
The leucine residue within Leu-Ala carries the primary anabolic signalling potential. The essential amino acid leucine (LEU) plays a crucial role in promoting resistance-training adaptations. Leucine is well-established as a key regulator of muscle protein synthesis (MPS); it activates the mTOR pathway, which is critical for initiating protein translation and muscle growth. Once Leu-Ala is hydrolysed after absorption, the liberated leucine can activate mTORC1 signalling in skeletal muscle, stimulating the phosphorylation of downstream targets including p70S6K and 4E-BP1, which in turn upregulate the initiation of mRNA translation and protein synthesis. Research on the closely related dipeptide dileucine (Leu-Leu) has demonstrated that the focus within nutritional science has shifted towards understanding the role of food-borne dipeptides and their incorporation as components of anabolic feeding formulations, with early evidence suggesting absorption rates of dipeptides can be similar to, and at times even exceed, those of comparable amino acids.
4.4 Alanine and the Glucose-Alanine (Cahill) Cycle
The alanine component of Leu-Ala participates, once released, in the glucose-alanine cycle — a central metabolic pathway that links muscle nitrogen export to hepatic gluconeogenesis. Alanine is quantitatively the primary amino acid released by muscle and extracted by the splanchnic bed in postabsorptive as well as prolonged fasted humans; the hepatic capacity for conversion of alanine to glucose exceeds that of all other amino acids. The physiological roles of this cycle include transport of nitrogen in a non-toxic form and of the gluconeogenic substrate pyruvate to the liver, thereby shifting the metabolic burden associated with nitrogen disposal and glucose regeneration to the liver. Furthermore, branched-chain amino acids (including leucine) serve as nitrogen donors in muscles, where glutamate acts as a nitrogen source for alanine synthesis from pyruvate. This establishes a direct biochemical link between the two amino acid moieties in Leu-Ala: leucine's transamination in muscle directly generates the glutamate required for alanine synthesis, meaning that the leucine and alanine residues in Leu-Ala are interconnected within the same nitrogen-handling metabolic loop.
4.5 BCAA Catabolism and Alanine as a Rate-Limiting Co-factor
Dietary supplements containing BCAAs alone may not be effective in controlling muscle protein turnover, due to the rate-limiting bioavailability of other amino acids involved in BCAA metabolism. L-Alanine has specifically been identified as a controlling element in BCAA catabolism. Evaluation of an oral formulation containing BCAAs combined with increasing concentrations of L-Alanine, an amino acid controlling BCAA catabolism, confirmed the ability of alanine to boost BCAA bioavailability. This provides a mechanistic justification for pairing leucine with alanine in a single dipeptide molecule: the alanine moiety may help sustain the metabolic context in which leucine is most efficiently utilized.
4.6 Fluorimetric Utility
L-Leucyl-L-Alanine is also used as a fluorescence intensifier in fluorimetric methods for the determination of phenylalanine. This application is purely analytical and not relevant to dietary supplementation, but reflects the compound's utility in clinical laboratory settings, particularly in neonatal phenylketonuria (PKU) screening.
5. Scientific Evidence by Area of Use
Important preliminary note on evidence quality: L-Leucyl-L-Alanine as a discrete dietary supplement ingredient has not been the subject of dedicated, published human clinical trials identified in the peer-reviewed literature to date. The scientific evidence reviewed here draws on: (a) direct biochemical characterisation of Leu-Ala itself; (b) human clinical trials examining closely analogous leucine-containing dipeptides, most notably dileucine (Leu-Leu); and (c) mechanistic studies on the constituent amino acids and dipeptide transport. Findings from analogue compounds and mechanistic studies cannot be directly extrapolated to Leu-Ala without dedicated human trials. All evidence gaps are explicitly noted.
5.1 Muscle Protein Synthesis and Resistance Training Performance
Mechanistic and In Vitro Evidence
The plausibility of Leu-Ala as a muscle anabolic supplement rests on its leucine content and the PepT1 absorption mechanism described in Section 4. The most directly relevant human evidence concerns dileucine (Leu-Leu), not Leu-Ala per se. In a randomized, double-blind, crossover human trial published in the Journal of Applied Physiology (Paulussen et al., 2021), ten healthy young men consumed either 2 g of leucine or 2 g of dileucine. Cumulative (0–180 min) MPS increased in the dileucine condition (0.075 ± 0.032%·h⁻¹), but not in the leucine condition (0.047 ± 0.029%·h⁻¹; P = 0.023). Results showed that dileucine ingestion elevated plasma dileucine concentrations and muscle protein turnover by stimulating MPS in young men. This is mechanistically relevant because dileucine represents a particularly intriguing compound due to its unique dipeptide structure and its potential to facilitate more efficient absorption and utilization than leucine alone; it is transported into the intestinal endothelium via the PepT1 H⁺/peptide cotransporter, potentially making it more rapidly available to muscle tissue.
Whether the same advantage applies to Leu-Ala is theoretically plausible (both use PepT1), but has not been demonstrated in published human trials. The alanine C-terminus of Leu-Ala differs from the leucine C-terminus of dileucine, meaning the two compounds have different affinities for PepT1 and may be hydrolysed at different rates. Direct evidence for Leu-Ala's MPS effects in humans is currently absent from the published record.
Clinical Trial Evidence (Dileucine Analogue — Longer-Term)
A 2025 randomized, double-blind, placebo-controlled trial examined 10-week resistance training adaptations. Using a randomized, double-blind, placebo-controlled approach, 34 resistance-trained males (age: 28.3 ± 5.9 years) consumed 2 grams of either dileucine monohydrate, leucine, or placebo while following a 4-day-per-week resistance training program for 10 weeks. Dileucine supplementation produced improvements in lower body strength and performance that were not observed in the free leucine or placebo groups. Despite its promising profile, research into the direct impact of dileucine supplementation remains sparse. These findings are cited here as the most proximate human evidence from the class of leucine-containing dipeptides, but should not be taken as direct evidence for Leu-Ala.
Evidence Strength Assessment
For Leu-Ala specifically: preclinical and mechanistic only — no human MPS trials identified. For the class of leucine-containing dipeptides: limited but promising, based on two small human trials (n = 10 and n = 34), both with notable limitations in sample size, sex restriction (males only), and absence of direct comparison against Leu-Ala. Further trials specifically examining Leu-Ala are needed before conclusions can be drawn.
5.2 Anti-Catabolic Activity / Muscle Preservation
Biochemical and In Vitro Evidence
L-Leucyl-L-Alanine is a dipeptide found to inhibit ubiquitin-mediated protein degradation. Ubiquitin-mediated degradation via the 26S proteasome is a primary driver of skeletal muscle atrophy in conditions including immobilisation, malnutrition, sepsis, cancer cachexia, and ageing. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins; inhibition of the 26S proteasome prevents this targeted proteolysis, affecting multiple signalling cascades within the cell. The capacity of Leu-Ala to inhibit this pathway in cell-based assays has been noted in biochemical catalogues, but the specific published study or studies demonstrating this activity for Leu-Ala — beyond the citation in biochemical supplier literature — were not directly accessible in full-text form during this review. The mechanism remains plausible but incompletely characterised.
BCAAs are recognized as potentially helpful dietary supplements to support skeletal muscle anabolism, particularly for athletes and fitness enthusiasts, as well as for elderly people to counteract age-related sarcopenia. This broad category of evidence applies to leucine-containing formulations generally; Leu-Ala is one member of that chemical space.
Evidence Strength Assessment
In vitro only for Leu-Ala's direct anti-catabolic action. Indirect evidence from constituent amino acid research is stronger, but cannot be attributed specifically to the dipeptide form.
5.3 BCAA Bioavailability Enhancement
Pre-Clinical Evidence
A study evaluated the in vivo and ex vivo effects of a 4-week treatment with an oral formulation combining BCAAs with increasing concentrations of L-Alanine in a murine model of physiological exercise; a preliminary pharmacokinetic study confirmed the ability of alanine to boost BCAA bioavailability. While this study used free alanine rather than the Leu-Ala dipeptide, it provides mechanistic support for the theoretical advantage of combining leucine and alanine in the same molecule: alanine appears to facilitate the metabolic utilisation of leucine by providing rate-limiting intermediates in BCAA catabolism.
The administration of leucine alone can ultimately lead to depletion of isoleucine and valine, since it activates the oxidation of all BCAAs. Whether the co-administration of alanine within the Leu-Ala dipeptide ameliorates this imbalance is an open research question.
Evidence Strength Assessment
Preliminary animal model only. The specific combination as a pre-formed Leu-Ala dipeptide has not been studied for BCAA pharmacokinetics in humans.
5.4 Glucose Metabolism and Hepatic Gluconeogenesis
Mechanistic Evidence
The alanine moiety of Leu-Ala participates in gluconeogenesis after hydrolysis. The glucose-alanine cycle is used primarily as a mechanism for skeletal muscle to eliminate nitrogen while replenishing its energy supply; glucose oxidation produces pyruvate, which can undergo transamination to alanine, a reaction catalyzed by alanine transaminase (ALT). Insulin inhibits gluconeogenesis by reducing hepatic alanine uptake; in contrast, in diabetes, an increase in hepatic alanine extraction is observed; in prolonged fasting, diminished alanine release is the mechanism whereby gluconeogenesis is reduced. These metabolic relationships are well-established for free alanine, but whether Leu-Ala as a dipeptide provides meaningful advantages in glucose metabolism over free alanine supplementation has not been examined in human clinical studies.
Evidence Strength Assessment
Mechanistic / established biochemistry for the alanine moiety. No human trials specific to Leu-Ala and glycaemia identified.
5.5 Analytical and Diagnostic Applications
L-Leucyl-L-Alanine is used as a fluorescence intensifier in fluorimetric methods for the determination of phenylalanine. This application has been documented in the clinical chemistry literature for neonatal metabolic screening and is distinct from any therapeutic or nutritional function.
6. Body Systems and Health Areas Associated with Leucine-Alanine
Skeletal Muscle System
The primary area of interest for Leu-Ala supplementation is skeletal muscle anabolism and anti-catabolism. L-Leucyl-L-Alanine inhibits ubiquitin-mediated protein degradation, a mechanism with theoretical relevance to conditions of muscle wasting. The leucine component activates the mTORC1–p70S6K signalling axis central to muscle protein synthesis. Dileucine elevates plasma concentrations and stimulates MPS rates more effectively than leucine alone; additionally, the rate at which leucine concentrations rise in the bloodstream could be a determining factor for the anabolic efficiency of dietary proteins. These findings from the analogous Leu-Leu dipeptide are mechanistically informative for Leu-Ala, as both share the N-terminal leucine residue and PepT1 transport.
Hepatic / Metabolic System
The liver is the primary site of alanine gluconeogenesis, as it is the only organ that houses the complete urea cycle. The alanine liberated from Leu-Ala hydrolysis participates in hepatic glucose production and nitrogen disposal, particularly relevant during fasting, exercise, and states of metabolic stress. In circumstances in which alanine is deficient, such as pregnancy and ketotic hypoglycemia of infancy, fasting hypoglycemia is accentuated.
Gastrointestinal and Absorptive System
PepT1 is located in the apical membrane of enterocytes and exhibits broad substrate specificity for dipeptides. The intestinal handling of Leu-Ala is thus distinct from free amino acid absorption, with implications for the rate and efficiency of leucine delivery to peripheral tissues. Several studies using mammals have demonstrated that intestinal PepT1 expression and dipeptide uptake are increased by feeding a high-protein diet.
Metabolic Nitrogen Balance
The glucose-alanine cycle transports nitrogen in a non-toxic form and provides the gluconeogenic substrate pyruvate to the liver, shifting the metabolic burden of nitrogen disposal and glucose regeneration. Leu-Ala, through its alanine component, participates in this nitrogen shuttle between muscle and liver, a function that is particularly active during prolonged exercise and caloric restriction.
7. Dosage Forms and Reported Dosages
No specific dosage regimens for L-Leucyl-L-Alanine (Leu-Ala) as a standalone dietary supplement have been established in the published human clinical literature. The compound does not appear as a standalone supplement ingredient in major clinical trials. Dosages reported in the literature apply to closely related formulations and should not be automatically applied to Leu-Ala:
- Dileucine (Leu-Leu) — Human MPS Study: Ingestion of 2 g of dileucine increased plasma dileucine concentrations and resulted in enhancement of muscle protein turnover by stimulating an increase in muscle protein synthesis rates in healthy young males.
- Dileucine (Leu-Leu) — 10-Week Resistance Training Trial: 34 resistance-trained males consumed 2 grams of dileucine monohydrate daily while following a 4-day-per-week resistance training program for 10 weeks.
- BCAAs + L-Alanine — Murine Model: A 4-week treatment with an oral formulation containing BCAAs combined with increasing concentrations of L-Alanine was evaluated in a murine model of physiological exercise. Specific milligram doses for human equivalence were not extrapolated in the available literature.
- BCAAs + L-Alanyl-L-Alanine — Pharmaceutical Patent: A patent composition described between 0.6 and 1 g of L-Leucine, between 0.3 and 0.5 g of L-Isoleucine, between 0.3 and 0.5 g of L-Valine, and from 0.5 g to 1.5 g of L-Alanyl-L-Alanine per unit dose, intended for prevention or treatment of muscle wasting in an animal model context.
Available preparation forms for L-Leucyl-L-Alanine in research-grade materials include: crystalline powder and monohydrate forms (as referenced in chemical catalogue descriptions such as "L-Leucyl-L-Alanine Monohydrate A.R."). In supplement products, leucine-containing dipeptides are typically delivered in powder, capsule, or tablet form as part of protein hydrolysate blends.
8. Safety Considerations and Interactions
General Safety Profile
L-Leucyl-L-Alanine has not been the subject of dedicated human safety or toxicology trials. Its constituent amino acids — L-leucine and L-alanine — are endogenous metabolites present in all dietary proteins and are classified as GRAS (Generally Recognized As Safe) by the U.S. FDA at nutritional intake levels. The dipeptide itself, being a simple two-amino-acid compound readily hydrolysed in the gastrointestinal tract, is expected to share the safety profile of its constituent amino acids under normal dietary conditions. Research-grade suppliers note the compound is provided for research use only and is not intended for human therapeutic use in isolated, high-purity form.
Considerations Specific to Leucine
The administration of leucine alone can ultimately lead to depletion of isoleucine and valine, since it activates the oxidation of all BCAAs. Supplementation with isolated leucine — or a leucine-dominant dipeptide such as Leu-Ala — without co-supplementation of the other BCAAs raises the theoretical concern of relative BCAA imbalance. This is a pharmacologically plausible consideration, not merely theoretical: dietary supplements containing BCAAs alone may not be effective in controlling muscle protein turnover, due to the rate-limiting bioavailability of other amino acids involved in BCAA metabolism.
Where protein intake is already adequate, leucine supplementation may not be of benefit to individuals due to maximal MPS likely already being achieved. This underscores the context-dependency of leucine-containing supplement benefits.
Considerations Specific to Alanine
Insulin inhibits gluconeogenesis by reducing hepatic alanine uptake; in contrast, in diabetes, an increase in hepatic alanine extraction is observed in the face of diminished circulating substrate. Individuals with insulin-related metabolic disorders or altered glucose metabolism may experience differential effects from alanine supplementation compared to metabolically healthy individuals. Elevated hepatic alanine uptake in diabetic states, as noted in the classic Metabolism literature, suggests that the gluconeogenic effects of free alanine (derived from Leu-Ala hydrolysis) could be quantitatively different in diabetic versus non-diabetic individuals, though no specific trial data on Leu-Ala in diabetic populations were identified.
Potential Drug Interactions
No pharmacokinetic drug-interaction studies specific to L-Leucyl-L-Alanine were identified in the peer-reviewed literature. The compound's rapid hydrolysis to free amino acids in the gastrointestinal tract suggests a low likelihood of direct pharmacokinetic interactions with most drugs. Theoretically, any agent affecting mTOR signalling (e.g., rapamycin analogues used as immunosuppressants) could interact with the anabolic effects of the leucine component, and gluconeogenesis-altering drugs or insulin could modify alanine's metabolic fate, but no interaction studies specific to Leu-Ala have been published.
Populations Requiring Particular Attention
No specific contraindications for L-Leucyl-L-Alanine have been established. General considerations for leucine and BCAA supplementation apply:
- Individuals with maple syrup urine disease (MSUD) or other BCAA metabolism disorders should not use concentrated leucine supplements without metabolic supervision.
- Patients with hepatic insufficiency may have impaired alanine gluconeogenesis, altering the metabolic fate of the alanine component; this is a mechanistic concern based on established alanine biochemistry rather than specific Leu-Ala trial data.
- The compound is classified as for research use only in most biochemical supply catalogues, reflecting the absence of approved human therapeutic dosing regimens rather than documented harm.
9. Summary of Evidence Quality
The following table summarises the state and quality of the evidence for each proposed area of use:
- Muscle protein synthesis stimulation (direct Leu-Ala data): In vitro / mechanistic only. No human clinical trials identified.
- Muscle protein synthesis stimulation (leucine dipeptide class): Limited human evidence (two small RCTs on dileucine, n = 10 and n = 34), promising but not yet robust.
- Inhibition of ubiquitin-mediated protein degradation: In vitro evidence; no human trials for Leu-Ala.
- BCAA bioavailability enhancement: Animal model evidence for BCAA + alanine combinations; no human dipeptide trial data for Leu-Ala.
- Glucose-alanine cycle / hepatic gluconeogenesis: Mechanistic evidence well-established for the alanine moiety; no trials specific to Leu-Ala as a dipeptide.
- Anti-sarcopenic / muscle-wasting applications: Theoretical / animal model; no human trials for Leu-Ala.
Overall, L-Leucyl-L-Alanine occupies an early-stage research space. Its chemical identity and endogenous occurrence are well-established; its biological activity at the biochemical level (UPS inhibition, PepT1 transport, constituent amino acid functions) is mechanistically coherent; but the evidence base for its use as a discrete dietary supplement in humans is as yet essentially absent from the published record. Claims made about Leu-Ala in the supplement marketplace that go beyond these established mechanistic grounds are not yet supported by published clinical trial evidence.
References
Go back